HeartWare International Inc  

(Public, NASDAQ:HTWR)   Watch this stock  
Find more results for HTWR
-0.53 (-1.10%)
After Hours: 47.86 0.00 (0.00%)
Nov 30, 5:36PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 47.36 - 49.24
52 week 34.70 - 95.59
Open 48.66
Vol / Avg. 189,101.00/405,035.00
Mkt cap 838.23M
P/E     -
Div/yield     -
EPS -4.22
Shares 17.32M
Beta 0.18
Inst. own 122%
Feb 24, 2016
Q4 2015 HeartWare International Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Dec 8, 2015
HeartWare International Inc at Oppenheimer Healthcare Conference - 10:20AM EST - Add to calendar
Dec 1, 2015
HeartWare International Inc at Piper Jaffray Healthcare Conference - 3:00PM EST - Add to calendar
Nov 19, 2015
HeartWare International Inc at Canaccord Genuity Medical Technology & Diagnostics Forum - Webcast
Nov 11, 2015
HeartWare International Inc at Credit Suisse Healthcare Conference
Nov 5, 2015
HeartWare International Analyst and Investor Meeting - Webcast
Oct 29, 2015
Q3 2015 HeartWare International Inc Earnings Release
Oct 29, 2015
Q3 2015 HeartWare International Inc Earnings Call - Webcast
Sep 9, 2015
HeartWare International Inc at Wells Fargo Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -45.92% -6.96%
Operating margin -39.50% -0.04%
EBITD margin - -5.37%
Return on average assets -24.52% -4.54%
Return on average equity -61.22% -9.51%
Employees 585 -
CDP Score - -


500 Old Connecticut Path
United States - Map
+1-508-7390873 (Phone)
+1-508-7390948 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Heartware International, Inc. is a medical device company. The Company develops and manufactures miniaturized implantable heart pumps or ventricular assist devices for patients suffering from advanced heart failure. The HeartWare Ventricular Assist System (HVAD System), which includes a ventricular assist device (VAD) or blood pump, patient accessories and surgical tools, provides circulatory support for patients in the advanced stage of heart failure. The core of the HVAD System is a continuous flow blood pump, the HVAD pump. The HVAD System is designed to be implanted adjacent to the heart, avoiding abdominal surgery, directly adjacent to the heart. The Company's hybrid system is used for suspending the impeller. The impeller is suspended within the pump housing by the opposing forces of passive magnets and hydrodynamic thrust generated by the pump impeller, which circulates a cushion of blood.

Officers and directors

C. Raymond Larkin Jr. Independent Chairman of the Board
Age: 66
Bio & Compensation  - Reuters
Douglas Evan Godshall M.B.A. President, Chief Executive Officer, Director
Age: 50
Bio & Compensation  - Reuters
Seth L. Harrison M.D. Deputy Chairman of the Board
Age: 54
Bio & Compensation  - Reuters
Peter F. McAree Chief Financial Officer, Senior Vice President, Treasurer
Age: 50
Bio & Compensation  - Reuters
Jeffrey A. LaRose Executive Vice President, Chief Scientific Officer
Age: 52
Bio & Compensation  - Reuters
Lawrence Knopf Senior Vice President, General Counsel, Secretary
Age: 53
Bio & Compensation  - Reuters
James Schuermann Senior Vice President - Sales and Marketing
Age: 46
Bio & Compensation  - Reuters
Mark Strong Senior Vice President, Research and Development and Quality Assurance
Age: 43
Bio & Compensation  - Reuters
Robert Yocher Senior Vice President, Regulatory Affairs
Age: 63
Bio & Compensation  - Reuters
Katrin Leadley M.D. Chief Medical Officer
Age: 52
Bio & Compensation  - Reuters